CD274 and neoplasm: Based on these findings, the National Comprehensive Cancer Network (NCCN) guidelines recommend nivolumab and pembrolizumab for metastatic anal cancer after first-line chemotherapy, regardless of the MSI/MMR status, as PD-L1 expression and high tumor mutational load may contribute to their efficacy.